AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca oncology — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Therapy Area & Region Tables
Latest, FY2025
23,698
Period ended Dec 31, 2025
Change on a year earlier
+16.9%
20,275 in FY2024
History
10 years
Since FY2016
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23,698 | +16.9% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 20,275 | +18.3% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 17,145 | +17.2% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 14,631 | +12.1% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 13,048 | +20.3% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 10,850 | +25.2% | Form 6-K FY2020Q4 Earnings Release ↗ |
| FY2019 | Dec 31, 2019 | 8,667 | +43.8% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 6,028 | +49.8% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 4,024 | +18.9% | Form 20-F (filed 2019-03-05) ↗ |
| FY2016 | Dec 31, 2016 | 3,383 | – | Form 20-F (filed 2019-03-05) ↗ |
Breakdown
What makes up oncology — worldwide product sales ($m)
- Oncology — Worldwide YoY actual (%)17.0% · FY2025
- Oncology — Worldwide YoY CER (%)16.0% · FY2025
- Oncology — US product sales ($M)11,187 · FY2025
- Oncology — Emerging Markets product sales ($M)5,350 · FY2025
- Oncology — Europe product sales ($M)4,880 · FY2025
- Oncology — Established RoW product sales ($M)2,281 · FY2025
- Tagrisso (osimertinib) — Worldwide product sales ($M)7,254 · FY2025
- Imfinzi (durvalumab) — Worldwide product sales ($M)6,063 · FY2025
- Calquence (acalabrutinib) — Worldwide product sales ($M)3,518 · FY2025
- Lynparza (olaparib) — Worldwide product sales ($M)3,279 · FY2025
- Enhertu (trastuzumab deruxtecan — direct product sales) — Worldwide product sales ($M)977 · FY2025
- Truqap (capivasertib) — Worldwide product sales ($M)728 · FY2025
- Zoladex (goserelin) — Worldwide product sales ($M)1,106 · FY2025
- Imjudo (tremelimumab) — Worldwide product sales ($M)346 · FY2025
- Datroway (datopotamab deruxtecan — direct product sales) — Worldwide product sales ($M)2 · FY2025
- Other Oncology medicines — Worldwide product sales ($M)425 · FY2025
Cite this data
StockData. (2026). AstraZeneca Oncology — Worldwide product sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_oncology_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.